Cargando…

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients. Over the past two decades, remarkable preclinical efforts to understand MM biology have led to the clinical approval of several targeted and immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnstone, Megan, Vinaixa, Delaney, Turi, Marcello, Morelli, Eugenio, Anderson, Kenneth Carl, Gulla, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406519/ https://www.ncbi.nlm.nih.gov/pubmed/36010596 http://dx.doi.org/10.3390/cells11162519

Ejemplares similares

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
por: Yamamoto, Leona, et al.
Publicado: (2021)

Multiple myeloma: the (r)evolution of current therapy and a glance into the future
por: Gulla', Annamaria, et al.
Publicado: (2020)

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
por: Tagliaferri, P, et al.
Publicado: (2012)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment
por: Milan, Enrico, et al.
Publicado: (2023)

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells
por: Di Martino, Maria Teresa, et al.
Publicado: (2014)

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
por: Zhang, Lu, et al.
Publicado: (2012)

Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Serrano-del Valle, Alfonso, et al.
Publicado: (2019)

Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2019)

VAD chemotherapy as remission induction for multiple myeloma.
por: Anderson, H., et al.
Publicado: (1995)

Talquetamab: A promising immunotherapy for multiple myeloma
por: Tariq, Amna, et al.
Publicado: (2023)

Promises and challenges in pharmacoepigenetics
por: Smith, Delaney A., et al.
Publicado: (2023)

Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Serrano Del Valle, Alfonso, et al.
Publicado: (2019)

BCMA in Multiple Myeloma—A Promising Key to Therapy
por: Kleber, Martina, et al.
Publicado: (2021)

Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling
por: Turi, Marcello, et al.
Publicado: (2023)

Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2018)

Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling
por: Waad Sadiq, Zeinab, et al.
Publicado: (2023)

DNA polymerases as chemotherapy targets: promise and challenges
por: Eckert, Kristin A., et al.
Publicado: (2019)

Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
por: Castella, Maria, et al.
Publicado: (2018)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises
por: Alkharabsheh, Omar, et al.
Publicado: (2021)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Antibody-Based Therapies in Multiple Myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2011)

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma
por: Robertson, J D, et al.
Publicado: (2000)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma
por: Li, Rong, et al.
Publicado: (2020)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

New Frontiers in the Treatment of Multiple Myeloma
por: Hwang, Janice Jin, et al.
Publicado: (2006)

PB2397: TRANSCRIPTOME ANALYSIS OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS EXPRESSING MYD88 L265P REVEALS CD44, LGALS3, NFKBIZ AND BATF AS DOWNSTREAM TARGETS OF ONCOGENIC NF-ΚB SIGNALING.
por: Turi, Marcello, et al.
Publicado: (2023)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

P01.15. Multiple Myeloma, chemotherapy and curcumin
por: Panutich, E, et al.
Publicado: (2012)

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2013)

Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
por: Scognamiglio, Immacolata, et al.
Publicado: (2014)

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
por: Malard, Florent, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ccagemanpki4f85hsjskbu762